Top Markets
#1 Islamic Coin Islamic Coin +151.49%
#2 DOVU DOVU +48.16%
#3 Velvet Velvet +44.46%
#4 Akedo Akedo +40.57%
#5 Black Phoenix Black Phoenix +33.98%
#6 Cross Cross +24.15%
#7 Cap Cap +20.35%
#8 DoubleZero DoubleZero +14.60%
#9 Tutorial Tutorial +11.59%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +9.77%
Coin of the day
Islamic Coin Islamic Coin
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
Clasificación en acciones #39467
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Precio por acción
$0.11725176
Última sincronización: 2025-07-14
Capitalización bursátil
$481.50K
Cambio (1 día)
-0.20%
Cambio (1 año)
0.00%
País
FR
Comercio PHAXIAM Therapeutics S.A. (PHXM)

Categoría

Healthcare
Ratio P/S de PHAXIAM Therapeutics S.A. (PHXM)
Ratio P/S al August 2026 TTM: 0.76
Según los informes financieros más recientes y el precio de las acciones de PHAXIAM Therapeutics S.A., el ratio P/S actual (TTM) es 0.76. Al final de 2022, el ratio P/S era 1.71.
Historial del ratio P/S de PHAXIAM Therapeutics S.A. desde 2016 hasta 2026
Ratio P/S al final de cada año
Año Ratio P/S Cambiar
2026 (TTM) 0.76 -94.94%
2023 15.05 779.26%
2022 1.71 -85.75%
2021 12.01 -65.83%
2020 35.16 54.56%
2019 22.75 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
Ratio P/S de empresas similares o competidoras
Empresa Ratio P/S Diferencia del ratio P/S País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.88 1,197.20%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.30 1,252.63%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.98 553.71%
BE